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Summary
Purpose: Data on the blood pharmacokinetics of vigabatrin, an antiepileptic drug
with a unique and novel mechanism of action, in the rat are sparse. Additionally, little
is known of the kinetics of vigabatrin in the central cerebrospinal fluid (CSF)
compartment. We therefore investigated the rate of penetration into and the
inter-relationship between serum and CSF compartments following systemic admin-
istration of vigabatrin in the rat.
Methods: Sprague—Dawley rats were implanted with a jugular vein catheter and a
cisterna magna catheter for blood and CSF sampling, respectively. Vigabatrin was
administered by intraperitonial injection at three different doses (250, 500 and
1000 mg/kg) and blood and CSF collected at timed intervals up to 8 h. Vigabatrin
concentrations in sera and CSF were determined by high performance liquid
chromatography.
Results: Vigabatrin concentrations in blood and CSF rose linearly and dose-depen-
dently and the time to maximum concentration (Tmax) was 0.4 and 1.0 h, respectively.
Vigabatrin is not protein bound in serum and its elimination from serum (mean t1/2
values, 1.1—1.4 h) is rapid and dose-independent. The efflux of vigabatrin from CSF
was significantly slower than that seen for serum (mean t1/2 values, 2.2—3.3 h).
Conclusions: The kinetics of vigabatrin are linear with rapid entry into CSF. However,
although vigabatrin CSF kinetics parallel that seen in serum, CSF vigabatrin concen-
trations represent only 2% of concentrations seen in serum and do not reflect free drug
concentrations in serum.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.. Published by Elsevier Ltd. All rights reserved.
44 X. Tong et al.g-aminobutyric acid (GABA), is the first of a series of
10 novel antiepileptic drugs that have entered clin-
ical use since 1989.1 Although a successful and well-
tolerated drug with particular efficacy in partial
seizures2,3 and is the treatment of first choice in
infantile spasms,4,5 it is now evident that long-term
vigabatrin treatment is associated with persistent
visual field problems.6—9 That the effects may be
irreversible and the fact that as many as 65% of
children and 40% of adults prescribed vigabatrin
present with concentric visual field constrictions,
has resulted in a substantial decline in its use.
Vigabatrin is effective in a variety of seizure
models including audiogenic seizures and seizures
induced by electroconvulsive shock, strychnine and
b-carbolines.10—12 The mechanism of action of vig-
abatrin is considered to be that of an irreversible
inhibition of GABA-transaminase, the enzyme
responsible for GABA catabolism.13—14 The resulting
increase in brain GABA concentrations parallels the
anticonvulsant effects of vigabatrin.15
Although thebloodpharmacokinetics of vigabatrin
in man is well-characterised such data are scarce in
the rat.16 Thus, whilst Valdizan et al.17 have reported
on the time course of vigabatrin in rat plasma after
single and multiple dose vigabatrin administration,
Sills et al.18,19 have reported plasma vigabatrin con-
centrations at a single time point after a single dose.
The time course of vigabatrin has also been reported
in rat CSF20 and brain21 and single time point CSF
(after multiple dose vigabatrin administration)22 and
brain (after single dose vigabatrin administra-
tion)18,19 vigabatrin concentrations has also been
documented. However, the exact relationship
between the central brain and peripheral blood
pharmacokinetics of vigabatrin is not known. In
patients with epilepsy, analysis of CSF obtained by
single lumber puncture after single dose vigabatrin
ingestion has shown vigabatrin to be present at 6 h
post-ingestion and for CSF vigabatrin concentrations
to be approximately 10—15% of blood concentra-
tions.23,24 CSF vigabatrin concentrations increase
dose-dependently and after multiple-doses CSF
vigabatrin concentration show a tendency to accu-
mulate.25 Whilst elevated CSF GABA concentrations
aremeasurable at 3-days post-vigabatrin administra-
tion, vigabatrin is not detectable at that time.
Although the CSF compartment is considered to
be kinetically indistinguishable from that of the
biophase or site of brain action of drugs that are
active in the brain,26—29 this has not been confirmed
for vigabatrin. Furthermore, CSF concentrations
may not necessarily reflect regional concentration
differences within the brain.30 Nevertheless, CSF
concentrations can provide insight as to what is
occurring in the brain and the present study useda well-established and validated rat model31—33 so
as to determine the blood and CSF kinetic inter-
relationship of vigabatrin after single dose vigaba-
trin (250, 500 and 1000 mg/kg) administration.Materials and methods
Animals
Male Sprague—Dawley rats (Charles River, Margate,
Kent, U.K.) weighing 300—350 g were used. They
were group housed in contiguous cages under a 12-
h light:12-hdark cyclewith free access towater anda
normal laboratory diet (SDS R and M number 1
expanded. Scientific Dietary Services, Witham,
Essex, U.K.). An ambient temperature of 25 8C was
maintained and all rats were allowed to acclimatise
to their new environment for about oneweek prior to
experimentation. All animal procedures strictly fol-
lowed Home Office regulations and were performed
under the Animal (Scientific Procedures) Act 1986.
Surgical procedures, CSF and blood
sampling
Rats were anaesthetised with 2% halothane (Merial
Animal Health Ltd., Dublin, Ireland) and catheters
implanted in the cisterna magna for CSF sampling,
and the right jugular vein for blood sampling, as
previously described.31 Post-surgery, animals were
individual housed in perspex cages. Two days later,
CSF and blood catheters were checked for patency
and CSF (20 ml) and blood (100 ml) samples were
simultaneously collected every 30 min for 1 h. Then
animals were randomly assigned to one of three
vigabatrin administration groups and administered
with vigabatrin (250, 500 and 1000 mg/kg consti-
tuted in saline) by intraperitonial (i.p.) injection.
Blood samples were withdrawn at 0.33, 0.66, 1, 1.5,
2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 and 8 h. In
order to prevent the development of hypovolaemia,
an equivalent volume of heparinised saline was
administered after each blood sampling. CSF sam-
ples were collected at 30 min intervals for 8 h. Blood
samples were collected in 0.5 ml polypropylene
tubes (Treff Lab, Dagersheim, Switzerland), vortex
mixed and centrifuged at 11,000 rpm for 5 min
(Sigma, 2K15). Supernatant sera and CSF were
stored frozen (70 8C) until analysed for vigabatrin
content.
Measurement of vigabatrin concentration
Vigabatrin concentrations in serum and CFS were
measured by a modification of the high performance
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Table 1 Pharmacokinetic parameters for serum after
250, 500 and 1000 mg/kg vigabatrin (VGB) administra-
tion
Rat Tmax
(h)
Cmax
(mmol/l)
AUC
(mmol h/l)
t1/2
(h)
VGB 250 mg/kg
1 0.3 1030.7 1455.7 1.0
2 0.7 585.7 893.8 1.2
3 0.3 1101.2 1765.8 1.3
4 0.3 1105.8 1820.5 1.2
5 0.3 925.8 1539.0 1.0
Mean 0.4 949.8 1495.0 1.1
S.E.M. 0.07 96.7 166.0 0.1
VGB 500 mg/kg
1 0.3 1803.8 4022.3 0.8
2 0.3 1578.4 3276.9 1.4
3 0.3 1528.5 3634.9 1.2
4 0.3 1289.4 2786.5 1.1
5 0.3 1558.7 3275.1 1.2
6 0.7 1814.2 3507.1 1.0
Mean 0.4 1595.5 3417.1 1.1
S.E.M. 0.06 79.8 169.2 0.1
VGB 1000 mg/kg
1 0.3 2744.1 6311.0 1.6
2 0.3 3412.5 7818.4 1.6
3 0.3 3310.8 8394.8 1.7
4 0.3 2992.3 6871.7 1.4
5 0.7 2733.8 7169.2 1.3
6 0.7 2581.0 7394.5 1.5
7 0.3 2815.0 6914.6 1.0
Mean 0.4 2941.3 7267.7 1.4
S.E.M. 0.06 118.4 258.0 0.1
Cmax, apparent maximum concentration; Tmax, apparent time
to maximum concentration; AUC, area under the serum con-
centration-time curve; t1/2, terminal half-life.liquid chromatography (HPLC) technique described
by Ratnaraj and Patsalos.34 A Gilson HPLC system
(Anachem Ltd., Luton, Beds) comprising of the fol-
lowing modules was used: two pumps (a Gilson 302
pump and a Gilson 305 pump), an autoinjector
(Gilsonmodel 234) and a Gilson 811C dynamic mixer,
and a Perkin-Elmer flurescence detector (Perkin-
Elmer Ltd., Beaconsfield, Bucks.) which was
set 250 nm (excitation) and 550 nm (emission). A
Hypersil BDS-C18, 3 mm, 125 mm  3 mm column
(Hewlett-Packard, Stockport, Cheshire, UK) and a
LiChrospher select B 4  4 (5 mm) pre-column (Hew-
lett-Packard) were used. Chromatograms were run
at 35 8C using a model 7955 column chiller (Jones
Chromatography Ltd., Hengoed, Mid. Glamorgan).
O-pthalaldehyde, the derivatization agent, and
L-norvaline, the internal standard were, purchased
from Sigma (Poole, Essex; BDH, Dagenham, Essex).
Vigabatrin S(+) was supplied by Marion Merrill Dow,
Inc (Cincinnati, OH, USA). All other chemicals were
of analytical grade. The lower limit of quantitation
of the assay, as determined by precision and accu-
racy, and whereby a coefficient of <10% was
targeted, was 1 mmol/l. Based on a signal-to-noise
ratio of 2:1, the limit of detection was 0.25 mmol/l.
The coefficient of variation of the within-batch
precision was 2% and for the between-batch preci-
sion the value was <4%. There is no interference
from any other antiepileptic drug that is currently
licensed for clinical use.
The procedure used for the determination of
the free non-protein-bound serum vigabatrin con-
centration was the same as for total vigabatrin
concentrations except that samples were first fil-
tered through an Amicon Cetrifree Micropartition
System (Amicon, Stonehouse, UK) using a Sigma
2K15 centrifuge with a temperature setting of 25 8C.
Data analysis
Pharmacokinetic parameters were calculated using
individual concentration versus time data sets
based on a one-compartment model. Time to max-
imum concentration (Tmax) and maximum concen-
tration (Cmax) were determined by visual inspection
of the concentration versus time curves. The area
under the concentration versus time curve (AUC) to
the last sample (serum or CSF) concentration was
obtained using the linear trapezoidal rule and
extrapolation to infinity by dividing the last con-
centration by the rate constant phase (b). The
elimination half-life (t1/2) was calculated from
the slope (lz), estimated by log linear regression
of the terminal phase of the concentration versus
time curve. Results are presented asmean  S.E.M.
Data were compared using Student’s t-test andmultiple comparisons were corrected for in the
statistical analysis.Results
Blood pharmacokinetics
Table 1 shows the pharmacokinetic parameters for
vigabatrin in serum for individual rats together with
the mean values, as calculated from concentration
versus time plots after 250, 500 and 1000 mg/kg
vigabatrin administration. Vigabatrin concentra-
tions rose linearly and dose-dependently. Rapid
absorption was demonstrated by the fact that Cmax
values were achieved at time of first sampling
(15 min post-dose). Concentrations subsequently
declined rapidly and the decline was exponential
(Fig. 1). Both Cmax and AUC values increased linearly
and dose-dependently. Vigabatrin t1/2 values were
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Figure 1 Vigabatrin concentration vs. time profiles in
serum after 250 mg/kg (^), 500 mg/kg (&) and 1000 mg/
kg (~) vigabatrin administration. Data are mean  S.E.M.
of 6—7 animals.
Figure 3 Vigabatrin concentration vs. time profiles in
CSF after 250 mg/kg (~), 500 mg/kg (^) and 1000 mg/kg
(&) vigabatrin administration. Data are mean  S.E.M. of
6—7 animals.
Table 2 Neuropharmacokinetic parameters for CSF
after 250, 500 and 1000 mg/kg vigabatrin (VGB) admin-
istration
Rat Tmax
(h)
Cmax
(mmol/l)
AUC
(mmol h/l)
t1/2
(h)
VGB 250 mg/kg
1 1.0 19.5 61.7 1.9
2 1.5 21.9 56.6 1.3
3 1.0 17.8 83.8 2.7
4 1.0 15.2 72.8 2.7
5 1.0 22.4 85.0 2.4
6 0.5 14.8 68.1 2.1
Mean 1.0 18.6 71.8 2.2
S.E.M. 0.2 1.3 4.4 0.2
VGB 500 mg/kg
1 0.5 20.7 95.8 3.4
2 1.0 30.4 108.2 2.8
3 1.0 46.6 189.6 2.8
4 1.0 27.3 99.8 4.3
5 0.5 36.4 130.8 2.5
6 1.0 29.5 114.0 3.21.1  0.1, 1.1  0.1 and 1.4  0.1 after 250, 500
and 1000 mg/kg administration, respectively, and
were not statistically different (p > 0.05).
A total of nine random sera, chosen to reflect a
range of sampling times (0.25—8 h) and vigabatrin
concentrations (13—1378 mmol/l), were analysed
for content of free non-protein-bound vigabatrin.
The free/total serum of vigabatrin concentration
ratio varied between 0.93 and 1.07 (mean
 S.E.M. = 0.995  0.01) and was not time or con-
centration dependent (Fig. 2).
CSF neuropharmacokinetics
Fig. 3 shows the corresponding CSF concentration
versus time profiles of vigabatrin. After drug admin-
istration, vigabatrin rapidly and readily penetrated
into the CSF compartment and vigabatrin was
detectable in CSF at the time of first sampling;
30 min post-dose. The calculated mean  S.E.M.
kinetic constants foe CSF, as calculated from the
concentration versus time plots, can be seen in
Table 2. The kinetic constants for individual rats
showed moderate variability within the three dose
groups. CSF vigabatrin concentrations peakedFigure 2 Vigabatrin free/total concentration ratio at
different vigabatrin concentrations (13—1378 mmol/l)
over time.somewhat later (mean Tmax, 0.8—1.0 h) than serum
vigabatrin (mean Tmax, 0.4 h), and were dose-inde-
pendent. Cmax and AUC values increased linearly
and dose-dependently and CSF t1/2 values althoughMean 0.8 31.8 123.0 3.2
S.E.M. 0.1 3.6 14.2 0.3
VGB 1000 mg/kg
1 1.0 37.2 180.6 3.5
2 1.0 31.1 129.4 2.9
3 1.0 80.1 412.7 3.6
4 1.0 47.0 267.4 4.1
5 0.5 45.2 190.8 2.9
6 0.5 63.3 239.1 2.9
Mean 0.8 50.6 236.7 3.3
S.E.M. 0.1 7.4 40.3 0.2
Cmax, apparent maximum concentration; Tmax, apparent time
to maximum concentration; AUC, area under the serum con-
centration-time curve; t1/2, terminal half-life.
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Figure 4 Relationship between vigabatrin concentra-
tions in serum and CSF. Data are those from 500 mg/kg
vigabatrin administration. The equation for linear regres-
sion is y = 0.0149 + 5.8625; r2 = 0.7106.
Figure 5 CSF/serum vigabatrin concentration ratios vs.
time after 250 mg/kg (&)), 500 (^) and 1000 (~) mg/kg
vigabatrin administration. Data are mean  S.E.M. of 6—7
animals.dose-independent were significantly longer than
that seen in serum ( p < 0.001). Compared to CSF,
mean Cmax and AUC serum vigabatrin values were
significantly larger and CSF/serum Cmax ratios ran-
ged 0.019 and 0.017. Nevertheless, CSF and serum
vigabatrin concentrations were linearly related
(Fig. 4; r2 = 0.7106).
Fig. 5 shows the vigabatrin CSF/serum concentra-
tion ratio over time after 250, 500 and 1000 mg/kg
vigabatrin administration. It can be seen that equili-
bration between thebloodandCSFcompartments (as
measured by a constant CSF/serum vigabatrin con-
centration ratio) was not achieved although there
was a tendency towards equilibration by 7—8 h post-
vigabatrin administration. For each sampling point,
the mean CSF/serum vigabatrin concentration ratio
was significantly lower than that of the corresponding
free/total serum (free fraction) vigabatrin concen-
tration ratio (p > 0.001).Discussion
There is a sparcity of data on the pharmacokinetics
of vigabatrin in animal species and those that are
published in relation to the rat represent composite
values obtained from individual animals killed at
different time points after drug administration.
Furthermore, the temporal pharmacokinetic inter-
relationship of vigabatrin in blood and CSF has
not been studied. Therefore we investigated the
inter-relationship using a rat model which allows
serial sampling of blood and CSF under conditions
that involve minimal animal handling and thus
pharmacokinetic parameters are obtained under
physiological conditions.
Vigabatrin was administered as a single dose (250,
500 or 1000 mg/kg) by intraperitonial injection and
the major (serum and CSF) pharmacokinetic findingsof this study are that: (1) the pharmacokinetics of
vigabatrin in serum are linear and dose-dependent;
(2) vigabatrin is not protein bound in serum; (3) the
elimination of vigabatrin from serum is rapid (mean
t1/2 values, 1.1—1.4 h) and independent of dose; (4)
vigabatrin rapidly (mean Tmax values, 0.8—1.0 h)
penetrated the blood-brain barrier and was detect-
able at time of first CSF sampling (30 min post-dose);
(5) although the CSF pharmacokinetics of vigabatrin
paralleled that seen in serum, CSF vigabatrin con-
centrations represented only 2% of serum vigabatrin
concentrations and did not reflect free drug concen-
trations in serum; (6) theeffluxof vigabatrin from the
CSF compartmentwas significantly slower (mean t1/2
values, 2.2—3.3 h) than that suggested by serum
values (mean t1/2 values, 1.1—1.4 h).
That the efflux of vigabatrin from the CSF com-
partment was significantly slower (mean t1/2 values,
2.2—3.3 h) than that suggested by serum values
(mean t1/2 values, 1.1—1.4 h), could be attributable
to a number of factors. One possibility is that vig-
abatrin concentrations were below the lower limit
of quantitation so that the estimation of CSF half-
life values was unreliable. However, this was not the
case since the lower limit of quantitation (1 mmol/l)
was below vigabatrin concentrations measured in
CSF (concentration range: 4.8—63.2 mmol/l). A sec-
ond possibility is that if one were to use a one
compartment model instead of a two compartment
model for fitting the serum concentration versus
time data, the serum elimination half-life would
be underestimated. However, the vigabatrin data
presented in Fig. 1 are well-described by a one
compartment model analysis and therefore this
possibility can be excluded.
Although there are reports of single point (at 2 h
of 4 h post-dose) concentration analysis of serum
vigabatrin in the rat after acute administration of
250, 500 and 1000 mg/kg vigabatrin, such data do
48 X. Tong et al.not allow any calculation of pharmacokinetic para-
meters.18,19 The study of Valdizan et al.17 reported
on the serum vigabatrin concentration versus time
profile after a single intraperitonial administration
of 200 mg/kg vigabatrin. Blood samples were col-
lected by heart puncture (thus, requiring a single rat
per time point) and samples were collected at 4, 24,
48 and 72 h post-dose. Although the calculated t1/2
value from these data is 11 h, the fact that viga-
batrin was not detectable at 48 h post-dose and that
the t1/2 value is based on only two time points (4 and
24 h) would suggest that the value cannot be con-
sidered as accurate. In the present study mean t1/2
values for serum vigabatrin, as calculated from
vigabatrin concentration versus time profiles char-
acterised by 16 time point over a sampling period of
8 h, varied between 1.1 and 1.4 h (Table 1).
That vigabatrin enters the CSF compartment was
confirmed by Halonen et al.22 who reported on cis-
ternal CSF concentrations 24 h after vigabatrin
administration (100 or 250 mg/kg) for 4, 8 and 12
consecutivedays. A further studyby the samegroup20
reported on cisternal CSF vigabatrin concentrations
after a single vigabatrin dose (1000 mg/kg) adminis-
tered intraperitoneally. CSF samples were collected
at 5, 24, 48 and 96 h after vigabatrin administration
and showed that vigabatrin concentrations were at
their highest at 5 h and interestingly vigabatrin was
still measurable in CSF samples collected at 96 h.
Unfortunately, the sparcity of the data do not allow
for any meaningful calculation of CSF pharmacoki-
netic data. However, comparing the CSF vigabatrin
concentrations achieved at 5 h post-dose with con-
centrations observed in the present study (Fig. 3)
vigabatrin concentrations are significantly different
(88 mmol/l versus 18 mmol/l for the present study).
The fact that the two studies used different rat
strains may in part explain the difference.
Vigabatrin is an ethyl analogue of GABA and as
such, and unlike GABA, passes through the blood
brain barrier and enters the brain where it elevates
brain GABA concentration via an inhibitory effect on
GABA-transaminase. Two physiochemical character-
istics which determine the rate and degree of entry
into the CSF and brain are lipid solubility and the
degree of serum protein binding, respectively.
Because vigabatrin has high water solubility, it
would not be expected to gain rapid entry into
the brain. Nevertheless, vigabatrin did rapidly enter
the central compartment since vigabatrin was
detectable in CSF at time of first sampling
(30 min; Fig. 3). Additionally, the rate of entry into
the CSF was not dose-dependent, as there was no
difference in Tmax values after vigabatrin dose
administration (250, 500 and 1000 mg/kg). Thus,
the transport of vigabatrin across the blood-CSFbarrier in the choroids plexus was not rate-limiting
at the concentration ranges achieved in the present
study. Indeed, serum and CSF vigabatrin concentra-
tions were linearly related (Fig. 4), although the
individual vigabatrin data points at the highest
vigabatrin concentrations do show a tendency to
scatter downwards which would suggest that there
is still distribution of vigabatrin from the serum to
the CSF at these points.
As the serum protein binding of a drug is a deter-
minantof theavailable drug that canenter thebrain/
CSF, itmight beexpected that vigabatrin,which is not
protein bound in serum, would be located in high
concentrations in these central compartments. How-
ever, this is not the case with CSF concentrations
representing but a small fraction (2%) of the concen-
trations observed in serum. In man the equivalent
figure is 10%.24 The reason for this is unknown, but it
should be noted that free drug concentrations in
blood and CSF will only be the same at steady-state,
and interestingly these data with vigabatrin parallel
that observed with another GABA acting drug, tiaga-
bine.35 In contrast, CSF concentrations of the anti-
epileptic drugs carbamazepine, lamotrigine,
phenobarbitone, phenytoin and primidone are a
direct reflection of the free (non-protein-bound)
concentrations in serum.26—28,36
In conclusion, this is the first study to investigate
the temporal pharmacokinetic inter-relationship of
vigabatrin in rat blood and CSF and shows that vig-
abatrin has linear peripheral and central kinetics and
with rapid penetration into the CSF compartment.
Although vigabatrin is not protein bound in serum,
CSF concentrations are only 2% of those in serum
and thus do not reflect free drug concentrations.Acknowledgements
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